TTNP vs MTLS

For growth investors, Materialise N.

V. (MTLS) is the stronger pick with -3. 6% revenue growth year-over-year, versus -100. 0% for Titan Pharmaceuticals, Inc. (TTNP). Materialise N. V. (MTLS) offers the better valuation at 35. 6x trailing P/E (25. 6x forward), making it the more compelling value choice. Analysts rate Materialise N. V. (MTLS) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Materialise N.

V. (MTLS) delivered a total return of -79. 7%, compared to -93. 4% for Titan Pharmaceuticals, Inc. (TTNP). Over 10 years, the gap is even starker: MTLS returned -19. 8% versus TTNP's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Materialise N.

V. (MTLS) is the lower-risk stock at 1. 26β versus Titan Pharmaceuticals, Inc. 's 1. 67β — meaning TTNP is approximately 33% more volatile than MTLS relative to the S&P 500.

By revenue growth (latest reported year), Materialise N.

V. (MTLS) is pulling ahead at -3. 6% versus -100. 0% for Titan Pharmaceuticals, Inc. (TTNP). On earnings-per-share growth, the picture is similar: Titan Pharmaceuticals, Inc. grew EPS 29. 4% year-over-year, compared to -43. 5% for Materialise N. V.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Materialise N.

V. (MTLS) is the more profitable company, earning 2. 9% net margin versus -280. 5% for Titan Pharmaceuticals, Inc. — meaning it keeps 2. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MTLS leads at 1. 9% versus -261. 1% for TTNP. At the gross margin level — before operating expenses — MTLS leads at 57. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Materialise N.

V. (MTLS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Titan Pharmaceuticals, Inc. (TTNP) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MTLS: -19. 8%, TTNP: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TTNP (Healthcare) and MTLS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.